BioSpace News Archive

Novan, Inc., announced its financial and operating results for the first quarter ended March 31, 2022 and provided a corporate update.

Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system disorders, today reported financial results for the first quarter ended March 31, 2022 and provided recent business highlights.

Beyond Air, Inc. announced that it will report financial results for its fiscal fourth quarter and year ended March 31, 2022 on Thursday, June 16, 2022.

scPharmaceuticals Inc. announced that the Company’s New Drug Application for FUROSCIX, a proprietary formulation of furosemide delivered via an on-body infusor for the treatment of congestion in patients with worsening heart failure, has been accepted for filing by the U.S. Food and Drug Administration.

Aclaris Therapeutics, Inc. announced that Dr. Neal Walker, President and CEO of Aclaris, will virtually present a company overview at the H.C. Wainwright Global Investment Conference, which will be available beginning on Tuesday, May 24, 2022 at 7:00 a.m. ET.

EyePoint Pharmaceuticals, Inc. announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2016 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635.

Zentalis Pharmaceuticals, Inc. announced that oncology clinical development veteran Kimberly Blackwell, MD, will succeed Anthony Sun, MD, as Chief Executive Officer.

Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today reported financial results for the first quarter ended March 31, 2022, and provided an overview of recent operational highlights and a pipeline update.

Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced financial results for the first quarter ended March 31, 2022 and provided recent corporate updates.

Altimmune, Inc., a clinical-stage biopharmaceutical company, announced that members of the Company’s management team will participate at the following investor conferences in May 2022: